Downloads: 17 | Views: 111 | Weekly Hits: ⮙3 | Monthly Hits: ⮙3

Review Papers | Pharmaceutical Science | India | Volume 13 Issue 3, March 2024 | Popularity: 6.2 / 10

Rate This Article!      

Nanotechnology in Bladder Cancer

Sobana, William Arputha Sundar, Aarthi, Sharmila Begum

Abstract: Bladder cancer (BC) is the second most common cancer of the urinary tract in men and the fourth most common cancer in women, and its incidence rises with age. There are many conventional methods for diagnosis and treatment of BC. There are some current biomarkers and clinical tests for the diagnosis and treatment of BC. For example, radiotherapy combined with chemotherapy and surgical, but residual tumours cells mostly cause tumour recurrence. In addition, chemotherapy after transurethral resection causes high side effects, and lack of selectivity, and low sensitivity in sensing. Therefore, it is essential to improve new procedures for the diagnosis and treatment of BC. Nanotechnology has recently sparked an interest in a variety of areas, including medicine, chemistry, physics, and biology. Nanoparticles (NP) have been used in tumour therapies as appropriate tools for enhancing drug delivery efficacy and enabling therapeutic performance. It is noteworthy, nanomaterial could be reduced the limitation of conventional cancer diagnosis and treatments. Since, the major disadvantages of therapeutic drugs are their insolubility in an aqueous solvent, for instance, paclitaxel (PTX) is one of the important therapeutic agents utilized to treating BC, due to its ability to prevent cancer cell growth. However, its major problem is the poor solubility, which has confirmed to be a challenge when improving stable formulations for BC treatment. In our review we have discussed about the technology and diagnosis and treatment in bladder cancer.

Keywords: bladder cancer, diagnosis, treatment, nanotechnology, chemotherapy

Edition: Volume 13 Issue 3, March 2024

Pages: 649 - 655

Click to Cite this Article

Similar Articles